EyePoint Pharmaceuticals (EYPT) AI Stock Analysis

• Market Cap: $1.25B
• Dividend Yield: N/A
• Average Volume (3M): 969.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: -7.38%
• EPS Growth: -49.03%
• Country: US
• Employees: 165
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 82,787,220
• 10 Day Avg. Volume: 876,077
• 30 Day Avg. Volume: 969,064
• PEG Ratio: -0.12
• Price to Book (P/B): 1.25
• Price to Sales (P/S): 9.69
• P/FCF Ratio: -3.22
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: 25.18
• Enterprise Value/Gross Profit: 26.76
• Enterprise Value/Ebitda: -5.08
• 1Y Price Target: $31.50
• Price Target Upside: 113.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $15.50 ▲(5.08% Upside)

EyePoint Pharmaceuticals' overall stock score reflects significant financial challenges, including declining revenues and persistent losses. However, strong technical momentum and positive corporate developments, such as successful trial updates and fundraising, provide a counterbalance. The company's strategic focus on innovative treatments and clinical progress offers potential for future growth, despite current valuation challenges.

Positive Factors

Multi-year cash runway from fundraising

A cash balance >$200M plus a $172M follow-on provides multi-year runway to complete pivotal DURAVYU programs and initial commercialization planning. This reduces near-term refinancing risk, allowing sustained clinical investment and strategic optionality over the next 18–24 months.

Rapid Phase III enrollment execution

Fast enrollment of >900 patients demonstrates operational execution, strong investigator engagement, and trial design attractiveness. Robust enrollment shortens development timelines, increases likelihood of timely mid-2026 topline readouts, and supports regulatory momentum for first-in-class sustained delivery.

Proprietary sustained-delivery platform and differentiated MOA

EyePoint's sustained-delivery platform and vorolanib's dual VEGF/IL-6 activity create structural differentiation versus frequent-injection therapies. If clinical efficacy and safety persist, this combination can reduce treatment burden, improve adherence, and establish durable competitive advantages in retinal disease markets.

Negative Factors

Sharp revenue decline

A dramatic quarter-over-year revenue drop signals weaker current product sales and reliance on non-recurring revenue recognition. Persistent top-line decline undermines internal funding ability, increasing dependence on external capital and making sustained commercial scaling more challenging absent near-term revenue recovery.

Negative operating cash flow and burn

Ongoing negative operating cash flow reflects clinical spending outpacing product cash generation. While current cash funds operations into 2027, sustained negative cash flow increases dilution or refinancing risk if clinical timelines extend or commercialization is delayed, pressuring long-term financial stability.

Deep negative profitability and ROE

Very large negative margins and ROE indicate material operating inefficiency and value destruction for shareholders. Until products reach the market and generate positive operating leverage, persistent losses will erode equity value and hinder the company's ability to deliver sustainable returns.

EyePoint Pharmaceuticals Business Overview & Revenue Model

Company Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

EyePoint Pharmaceuticals generates revenue primarily through the sale of its marketed products, which include therapeutics for eye diseases. The company also benefits from partnerships and collaborations with other pharmaceutical companies, which may involve licensing agreements, co-development deals, or royalties on sales of products that utilize EyePoint's proprietary technologies. Additionally, financial support from government grants and research funding can contribute to its revenue streams. The success of its products in the market, along with strategic alliances, plays a crucial role in driving the company's overall earnings.

EyePoint Pharmaceuticals Financial Statement Overview

Summary

EyePoint Pharmaceuticals faces significant financial challenges with declining revenues and persistent losses impacting profitability. Despite a strong gross profit margin and low leverage, negative cash flows and returns on equity highlight operational inefficiencies. Strategic improvements in cost management and revenue generation are crucial for future stability and growth.

Income Statement

EyePoint Pharmaceuticals shows a declining revenue trend with a negative revenue growth rate of -18.42% in the TTM. The gross profit margin remains strong at 94.08%, indicating efficient cost management. However, the company struggles with profitability, evidenced by a significant negative net profit margin of -485.95% and negative EBIT and EBITDA margins. This suggests challenges in managing operating expenses and achieving profitability.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.11, indicating conservative leverage. However, the return on equity is negative at -76.13%, reflecting ongoing losses and inefficiencies in generating returns for shareholders. The equity ratio stands at 79.52%, showing a strong equity base relative to total assets, which provides some stability.

Cash Flow

EyePoint Pharmaceuticals faces cash flow challenges with a negative operating cash flow and free cash flow. The free cash flow growth rate is positive at 10.08%, but the operating cash flow to net income ratio is negative, indicating cash flow issues relative to reported losses. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow aligns with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.34M	43.27M	46.02M	41.40M	36.94M	34.44M
Gross Profit	39.83M	39.56M	41.39M	33.08M	28.76M	28.61M
EBITDA	-210.01M	-129.23M	-69.00M	-96.62M	-50.15M	-35.49M
Net Income	-205.75M	-130.87M	-70.80M	-102.25M	-58.42M	-45.39M
Balance Sheet
Total Assets	251.69M	418.46M	355.18M	180.36M	263.37M	91.72M
Cash, Cash Equivalents and Short-Term Investments	204.02M	370.91M	331.05M	144.56M	211.56M	44.91M
Total Debt	21.30M	21.86M	4.91M	46.35M	39.20M	40.99M
Total Liabilities	51.51M	81.96M	88.86M	83.99M	78.99M	73.18M
Stockholders Equity	200.18M	336.50M	266.32M	96.37M	184.38M	18.54M
Cash Flow
Free Cash Flow	-213.59M	-130.28M	-1.61M	-67.16M	-50.25M	-14.80M
Operating Cash Flow	-210.91M	-126.23M	1.88M	-65.00M	-50.10M	-14.44M
Investing Cash Flow	47.28M	-219.35M	-3.31M	-17.27M	-33.12M	-362.00K
Financing Cash Flow	158.38M	164.02M	187.07M	-690.00K	216.90M	37.49M

EyePoint Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 14.75
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Neutral. The current price of 14.75 is below the 20-day moving average (MA) of 16.15, below the 50-day MA of 16.11, and above the 200-day MA of 11.67, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 39.64 is Neutral, neither overbought nor oversold. The STOCH value of 23.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EYPT.

EyePoint Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	66 Neutral	$1.43B	1,436.81	0.44%	―	26.54%	―
STOK	61 Neutral	$1.68B	47.08	15.02%	―	1128.17%	―
EYPT	58 Neutral	$1.25B	-4.93	-98.23%	―	-7.38%	-49.03%
TNGX	53 Neutral	$1.51B	-12.73	-51.65%	―	53.28%	21.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
URGN	50 Neutral	$997.97M	-5.98	―	―	8.00%	-10.15%
MGTX	47 Neutral	$624.61M	-3.66	-611.42%	―	96.83%	-61.92%

EyePoint Pharmaceuticals Corporate Events

EyePoint Pharmaceuticals Announces Official Name Change

On December 8, 2025, EyePoint, Inc. officially changed its name from EyePoint Pharmaceuticals, Inc. This change, which also involved amendments to the company’s by-laws, does not impact the trading of its common stock on the Nasdaq Global Market under the ticker symbol ‘EYPT’, nor does it affect the rights of the company’s security holders.

The most recent analyst rating on (EYPT) stock is a Hold with a $18.50 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

EyePoint Pharmaceuticals Receives Positive Phase 3 Trial Update

On November 19, 2025, EyePoint Pharmaceuticals announced a positive recommendation from the independent Data Safety Monitoring Committee for its ongoing pivotal Phase 3 trials of DURAVYU for treating wet age-related macular degeneration (wet AMD). The trials, named LUGANO and LUCIA, have shown no safety signals, and the DSMC recommended continuing without protocol changes. This strengthens confidence in DURAVYU’s safety profile, with topline data expected in mid-2026. The trials are significant as they evaluate a sustained release treatment potentially reducing the treatment burden for wet AMD, a condition requiring frequent interventions.

The most recent analyst rating on (EYPT) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

EyePoint Pharmaceuticals Files $200M Stock Offering Prospectus

On November 6, 2025, EyePoint Pharmaceuticals filed a prospectus supplement to its registration statement with the SEC, enabling a registered offering of up to $200 million in common stock. This move, under the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., signifies a strategic financial maneuver to potentially enhance the company’s capital, impacting its market positioning and stakeholder interests.

The most recent analyst rating on (EYPT) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.